{
  "authors": [
    {
      "author": "Syed Zubair Hussain"
    },
    {
      "author": "Ali Asghar"
    },
    {
      "author": "Mubasher Ikram"
    },
    {
      "author": "Najmul Islam"
    }
  ],
  "doi": "10.1186/1472-6823-13-29",
  "publication_date": "2013-08-14",
  "id": "EN116391",
  "url": "https://pubmed.ncbi.nlm.nih.gov/23937803",
  "source": "BMC endocrine disorders",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We report the case of a middle aged gentleman with metastatic papillary carcinoma of thyroid diagnosed in 2005. He was managed with total thyroidectomy, radioactive iodine and TSH suppressive therapy. Despite receiving radioactive iodine 530 mci cumulative dose, patient had persistant disease with lung metastasis. Therefore a TKI, sorafenib, was started. He developed hypopigmentation of the skin more prominent on face six weeks after starting sorafenib treatment.He also developed diarrhea, desquamation of hands and feet, hair loss over scalp, eye brows and moustache. Sorafenib treatment was discontinued. His diarrhea stopped in one week and after four weeks his skin became normalized whereas he regained his hairs in six weeks."
}